INTRODUCTION {#s1}
============

Variations in disease onset and/or severity have been observed in siblings with cystic fibrosis (CF) for decades ([@MCS004531WILC45]). The most notable differences relate to CF lung disease. Many factors have been suggested to explain discordances such as gender, meconium ileus, age of diagnosis, cystic fibrosis transmembrane conductance regulator (*CFTR*) genotype, acquisition of respiratory pathogens, treatment regimens, and, most recently, genetic modifiers ([@MCS004531WILC49]; [@MCS004531WILC36]; [@MCS004531WILC42]; [@MCS004531WILC11]; [@MCS004531WILC54]; [@MCS004531WILC48]).

Prior to the onset of routine early diagnosis through newborn screening (NBS), it was proposed from an influential sibling pair study that diagnosis at a younger age leading to early treatment initiation might account for lessened severity in the younger sibling ([@MCS004531WILC49]). Although NBS does lead to a reduction in the severity of outcomes for the majority of children ([@MCS004531WILC20]), there is subgroup known as "nonresponders," approximately one-third of patients, who do not show the same degree of benefit from early diagnosis ([@MCS004531WILC55]). After discovery of the *CFTR* gene ([@MCS004531WILC37]), studies on genotype--phenotype relationships, although illuminating with regard to pancreatic functional variations ([@MCS004531WILC36]; [@MCS004531WILC17]), did not succeed in explaining differences in the onset and severity of lung disease ([@MCS004531WILC38]; [@MCS004531WILC36]). In fact, observations on homozygous F508del patients revealed such great variability in respiratory disease outcomes that attention turned to the identification of genetic modifiers ([@MCS004531WILC11]; [@MCS004531WILC10]; [@MCS004531WILC48]). Application of genome-wide association studies (GWASs) has more recently facilitated identification of certain classes of modifiers resulting in phenotypic variation ([@MCS004531WILC10]).

Individual specific variable drug responses can present significant challenges for the effective and safe treatment of many human diseases. Pharmacogenomics (PGx) attempts to relate drug response to patient-specific genome in order to better customize therapeutic selections. We posited that the whole-genome sequencing (WGS) data generated for phenotypic modifier studies might simultaneously be useful for the extraction of PGx findings of relevance for patients with CF.

Here we report an investigation of non-*CFTR* genetic factors in three brothers with CF who showed considerable clinical variations in the course of disease manifestations, particularly during childhood. Their discordances led us to search for genetic modifiers and pharmacogenomics differences using a WGS-based approach. Our hypothesis is that genomic variation will help explain clinical differences among siblings.

RESULTS {#s2}
=======

Patient Phenotypes {#s2a}
------------------

All three brothers were confirmed by WGS to have a *CFTR* genotype of F508del/CFTRdele2,3 and no other *CFTR* variants. None had meconium ileus, each was diagnosed with a sweat chloride level of \>100 mmol/L, and all had pancreatic insufficiency. Their clinical histories are summarized in [Table 1](#MCS004531WILTB1){ref-type="table"}. Quantitative longitudinal evaluations of lung disease were performed and data are shown in [Figures 1](#MCS004531WILF1){ref-type="fig"} and [2](#MCS004531WILF2){ref-type="fig"}.

![Pulmonary function test results in the three brothers (i.e., percent predicted FEV1 \[ppFEV1\] values as related to age). The data obtained on three brothers are shown as A (eldest), B (middle), and C (youngest) and demonstrated that the youngest had better pulmonary function than his brothers. After 20 yr, the eldest brother deteriorated and reached 20% at 28 yr of age.](MCS004531Wil_F1){#MCS004531WILF1}

![Wisconsin chest X-ray scores ([@MCS004531WILC40]) in the three brothers as compared to published data ([@MCS004531WILC21]) from the Wisconsin randomized clinical trial (RCT) of the newborn screening (NBS) cohort in which a thoracic radiologist and pediatric pulmonologist rated chest radiographs independently, with their scores being averaged. The data obtained on three brothers are shown as A (eldest), B (middle), and C (youngest) and demonstrated that the youngest had lower and therefore milder lung disease than his brothers throughout childhood. In the case of the eldest brother labeled A, the scores assigned by the same pediatric pulmonologist were adjusted to conform with the averaging method. The gray shaded area labeled D represents the mean ± 95% confidence interval for the entire RCT cohort. (CXR) Chest X-ray.](MCS004531Wil_F2){#MCS004531WILF2}

###### 

Summary of clinical characteristics

  Characteristics                  Eldest brother    Middle brother         Youngest brother
  -------------------------------- ----------------- ---------------------- ------------------
  Gestational age (weeks)          38                38                     41
  Birth weight (g)                 2830              2410                   3520
  Year of birth                    1984              1990                   1992
  Age at diagnosis (weeks)         12                7                      5
  NBS (yes/no)                     No                Yes                    Yes
  IRT level (ng/mL)                NA^a^             234                    251
  Sweat Chloride (mEq/L)           104/98            111/110                110/107
  *CFTR* genotype                  F508del/dele2,3   F508del/dele2,3        F508del/dele2,3
  Meconium ileus                   No                No                     No
  Age at PERT (wk)                 NA^a^             36                     38
  Age at 1st AF acquisition (yr)   18                11                     14.75
  \% cultures revealing AF         31                77                     38
  Age of lung transplant (yr)      29                20                     \_\_\_\_^b^
  Other comorbidities              CFRD, CFLD        CFRD, pneumothoraces   \_\_\_\_^b^
  Age of death (yr)                \_\_\_\_^b^       24                     \_\_\_\_^b^

^a^Information not available or test not done.

^b^None at time of publication.

(NBS) Newborn screening, (IRT) immunoreactive trypsinogen, (PERT) pancreatic enzyme replacement therapy, (AF) *Aspergillus fumigatus*, (CFRD) cystic fibrosis--related diabetes, (CFLD) cystic fibrosis liver disease.

The eldest brother was diagnosed with CF at 3 mo of age because of failure to thrive. Despite initiation of pancreatic enzyme replacement therapy (PERT), he tracked under the fifth percentile for weight throughout childhood. After 12 yr of *Pseudomonas aeruginosa* (PA)-positive cultures and progressive lung disease, his sputum culture revealed *Aspergillus fumigatus* (AF) at 18 yr. He received a bilateral lung transplantation at 29 yr of age after his percent predicted forced expiratory volume in 1 sec (ppFEV1) had decreased to 20% and his Wisconsin chest X-ray (WCXR) score was rising dramatically ([Fig. 2](#MCS004531WILF2){ref-type="fig"}).

The middle brother was diagnosed with CF through NBS and began PERT at 36 wk of age when pancreatic insufficiency was demonstrated through protocol-guided studies ([@MCS004531WILC19]). Although PA was not cultured until 16 yr of age, he was noted by WCXR scores to have developed irreversible lung disease (i.e., WCXR \> 5) ([@MCS004531WILC21]) by 2 yr of age and had severely progressive lung disease between 5 and 14 yr ([Fig. 2](#MCS004531WILF2){ref-type="fig"}). His sputum culture first grew AF at age 11 yr. He was treated for AF with itraconazole, but eradication was unsuccessful. He underwent bilateral lung transplantation age 20 yr, and died at 24 yr because of multisystem organ failure.

The youngest brother was also diagnosed with CF through NBS. He had a relatively mild course of lung disease throughout most of childhood; this was clearly less severe than the cohort of other screened patients in the RCT ([Fig. 2](#MCS004531WILF2){ref-type="fig"}). After age 12 yr, he began to deteriorate in association with culturing AF. He has yet to acquire PA through his current age of 26 yr.

Modifiers of Cystic Fibrosis {#s2b}
----------------------------

Our WGS-based analysis identified five variants that might affect the brothers' phenotypes ([Table 2](#MCS004531WILTB2){ref-type="table"}). All three brothers were found to have a common heterozygous nonsynonymous variant in *EPHX1* previously shown to reduce enzyme activity by at least 20% ([@MCS004531WILC30]). A low activity of *EPHX1* has been identified as a risk factor for chronic obstructive pulmonary disease (COPD), and this specific variant has been associated with altered risk of pulmonary disease ([@MCS004531WILC59]; [@MCS004531WILC61]: [@MCS004531WILC8]; [@MCS004531WILC7]). Although association between variant homozygosity and increased risk of COPD was recently confirmed via comprehensive meta-analysis, the findings were not supported for variant heterozygosity ([@MCS004531WILC43]).

###### 

Genetic modifiers identified in the brothers

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene         Chr   DNA change          Variant type   Variant        dbSNP ID/ClinVar ID   AF(%)    Brother   Phenotype associations            
  ------------ ----- ------------------- -------------- -------------- --------------------- -------- --------- ------------------------ -------- ------------------------------------------------
  *EPHX1*      1     g.226019633T \> C   Missense       NM_000120.3\   rs1051740             31.65    10/24\    25/52\                   21/35\   COPD
                                                        c.337T \> C\                                  Het       Het                      Het      
                                                        p.Y113H                                                                                   

  *HFE*        6     g.26091179C \> G    Missense       NM_000410.3\   rs1799945             10.82    10/30\    14/29\                   32/32\   Hemochromatosis\
                                                        c.187C \> G\                                  Het       Het                      Hom      Liver disease\
                                                        p.H63D                                                                                    Type II diabetes

  *MBL2*       10    g.54531242G \> A    Missense       NM_000242.2\   rs5030737             5.48     15/23\    --                       13/28\   Respiratory tract infections\
                                                        c.154C \> T\                                  Het                                Het      Bronchiectasis\
                                                        p.R52C                                                                                    Lung function

  *PLG*        6     g.161137720G \> A   Missense       NM_000301.3\   rs756287836           0.0036   --        --                       13/28\   Chronic mucosal membrane inflammation\
                                                        c.712G \> A\                                                                     Het      Recurrent sinobronchial infections
                                                        p.D238N                                                                                   

  *SERPINA1*   14    g.94847262T \> A    Missense       NM_000295.4\   rs17580               2.34     --        18/40\                   21/35\   COPD\
                                                        c.863A \> T\                                            Het                      Het      Increased risk for pulmonary and liver disease
                                                        p.E288V                                                                                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Sequence coverage for each variant is provided along with the call made.

(Chr) Chromosome, (COPD) chronic obstructive pulmonary disease, (AF(%)) % allele frequency in gnomAD shown in percentages, (Het) heterozygous, (Hom) homozygous.

A known deleterious missense variant in *HFE* (p.H63D) was found to be heterozygous in the eldest and middle brothers and homozygous in the youngest. This variant is pathogenic for a mild form of hereditary hemochromatosis ([@MCS004531WILC22]). Although clinical hemochromatosis is mostly associated with p.C282Y homozygosity, there is evidence that p.H63D can act as a modifier for α1-antitrypsin deficiency liver and lung disease ([@MCS004531WILC34]). Functional variation in *HFE* has been associated with risk of infection in general ([@MCS004531WILC39]; [@MCS004531WILC47]; [@MCS004531WILC25]) and deteriorating lung function specifically in CF ([@MCS004531WILC60]).

A third variant of interest is the known deleterious variant in *MBL2* (D variant; p.R52C), which was heterozygous in the eldest and youngest brothers. MBL2 plays a role in immune function, activating the lectin complement pathway and leading to clearance by phagocytes. This variant is pathogenic for mannose-binding protein deficiency ([@MCS004531WILC31]). Variants in this gene have been associated with recurrent respiratory tract infections, bronchiectasis severity, and age-related decline in lung function ([@MCS004531WILC33]; [@MCS004531WILC28]; [@MCS004531WILC44]; [@MCS004531WILC51]). The presence of functional variants in *MBL2* has shown association with different aspects (lung function, infection, and survival) of CF in some studies ([@MCS004531WILC15]; [@MCS004531WILC46]).

The youngest brother was heterozygous for an ultra-rare, conserved, nonsynonymous predicted to be damaging variant (p.D238N) in a known kringle-binding domain in the plasminogen protein (*PLG*) ([@MCS004531WILC1]). Although not previously reported, this variant would be categorized as likely pathogenic based on American College of Medical Genetics and Genomics (ACMG) guidelines ([@MCS004531WILC53]). Functional variation in *PLG* is associated with plasminogen deficiency, which has been causally linked to a rare chronic inflammatory disease of the mucous membranes. PLG deficiency also predisposes patients to recurrent sinobronchial AF infections in immunocompromised individuals ([@MCS004531WILC67]).

Finally, a known deleterious variant in *SERPINA1* (PiS; p.E288V) was identified in the middle and youngest brothers. This variant is a known risk factor for COPD and a known pathogenic variant for α1-antitrypsin deficiency, which increases the risk for pulmonary and liver disease in both heterozygous and homozygous states ([@MCS004531WILC50]; [@MCS004531WILC27]). Other variants in this gene have been shown to modify CF-related disease ([@MCS004531WILC12]).

Pharmacogenomic Findings {#s2c}
------------------------

Pharmacogenomic variants categorized as level 1A, 1B, 2A, and 2B ([@MCS004531WILC62]) were identified for a number of drugs commonly used in the treatment of CF ([Table 3](#MCS004531WILTB3){ref-type="table"}). Whereas all three brothers are similar for a number of loci, there remain some notable differences. For example, several loci assessed (CRHR2, COL22A1, and ADRB2) have been associated with efficacy of the β2-adrenergic salbutamol ([@MCS004531WILC6]; [@MCS004531WILC52]; [@MCS004531WILC16]), with each brother having unique combinations. Of these, the middle brother might have the least benefit from albuterol. Similarly, the middle brother was unique in his *TMPT* haplotype associated with thiopurine (e.g., azathioprine) inactivation that would put him at higher risk of toxicity when treated with thiopurine drugs.

###### 

Pharmacogenomic findings relevant to the management of cystic fibrosis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Drugs            Eldest brother                                                                                                                                                                                                                                                                                  Middle brother                                                                                                                                                                                         Youngest brother
  ---------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tobramycin:\     *MT-RNR1*---patient is homoplastic (A) for this rs267606617 allele. Associated with decreased risk of aminoglycoside-induced hearing loss.                                                                                                                                                      *MT-RNR1*---patient is homoplastic (A) for this rs267606617 allele. Associated with decreased risk of aminoglycoside-induced hearing loss.                                                             *MT-RNR1*---patient is homoplastic (A) for this rs267606617 allele. Associated with decreased risk of aminoglycoside-induced hearing loss.
  Eldest −\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Middle +\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Youngest −                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Salbutamol:\     *CRHR2*---patient is homozygous (A/A) for the rs7793837 allele; associated with a better response (increased acute bronchodilation).\                                                                                                                                                           *CRHR2*---patient is heterozygous (A/T) for the rs7793837 allele; associated with intermediate response.\                                                                                              *CRHR2*---patient is homozygous (A/A) for the rs7793837 allele; associated with a better response (increased acute bronchodilation).\
  Eldest −\        *COL22A1*---patient is homozygous (C/C) for the rs6988229 allele; associated with a decreased bronchodilator response (FEV1).\                                                                                                                                                                  *COL22A1*---patient is homozygous (C/C) for the rs6988229 allele; associated with a decreased bronchodilator response (FEV1).\                                                                         *COL22A1*---patient is homozygous (C/C) for the rs6988229 allele; associated with a decreased bronchodilator response (FEV1).\
  Middle −\        *ADRB2*---patient is heterozygous (A/G) for the rs1042713 allele. Children with A/G genotype with asthma who are treated with salmaterol or salbutamol may have a decreased response to treatment than children with G/G genotypes, and better response than children with A/A genotype.        *ADRB2*---patient is homozygous (A/A) for the rs1042713 allele. Children with the AA genotype with asthma who are treated with salmeterol or salbutamol may have a decreased response to treatment.    *ADRB2*---patient is homozygous (A/A) for the rs1042713 allele. Children with the AA genotype with asthma who are treated with salmeterol or salbutamol may have a decreased response to treatment.
  Youngest −                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Omeprazole:\     *CYP2C19*\*1B/\*2B---intermediate-to-poor metabolizer. Patient may require lower doses of drugs metabolized by *CYP2C19* enzyme compared to normal/rapid metabolizers to avoid toxicity or switching to a drug independent of *CYP2C19* metabolism.                                             *CYP2C19*\*17/\*2B---intermediate metabolizer. Standard dosing guidelines generally apply.                                                                                                             *CYP2C19*\*1B/\*2B---intermediate-to-poor metabolizer. Patient may require lower doses of drugs metabolized by *CYP2C19* enzyme compared to normal/rapid metabolizers to avoid toxicity or switching to a drug independent of *CYP2C19* metabolism.
  Eldest −\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Middle −\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Youngest +\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Voricanazole:\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Eldest −\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Middle −\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Youngest −\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Other^a^                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Tacrolimus:\     *CYP3A5* (\*3/\*3)---patient is homozygous for the two alleles (rs776746 and rs28383479) that make up the *CYP3A5*\*3 haplotype.\                                                                                                                                                               *CYP3A5* (\*3/\*3)---patient is homozygous for the two alleles (rs776746 and rs28383479) that make up the *CYP3A5*\*3 haplotype.\                                                                      *CYP3A5* (\*3/\*3)---patient is homozygous for the two alleles (rs776746 and rs28383479) that make up the *CYP3A5*\*3 haplotype.\
  Eldest +\        Decreased metabolizer; may require a lower dose.                                                                                                                                                                                                                                                Decreased metabolizer; may require a lower dose.                                                                                                                                                       Decreased metabolizer; may require a lower dose.
  Middle +\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Youngest −                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Azathioprine:\   *TPMT* (\*1A/\*1A)---associated with (1) increased inactivation of thiopurines due to normal TPMT activity; (2) a decreased risk for toxicity when receiving thiopurine drugs and purine analogs. Patients may still be at risk for toxicity when taking thiopurine drugs and purine analogs.   *TPMT* (\*1/\*3A)---associated with (1) decreased inactivation of thiopurines due to deficient TPMT activity; (2) an increased risk for toxicity when receiving thiopurine drugs and purine analogs.   *TPMT* (\*1A/\*1A)---associated with (1) increased inactivation of thiopurines due to normal TPMT activity; (2) a decreased risk for toxicity when receiving thiopurine drugs and purine analogs. Patients may still be at risk for toxicity when taking thiopurine drugs and purine analogs.
  Eldest −\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Middle −\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Youngest −                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Prescribing information based on *CYP2C19* haplotypes is available for a number of other drugs, including the following: amitriptyline, citalopram, escitalopram, esomeprazole, clomipramine, clopidogrel, doxepin, imipramine, lansoprazole, moclobermide, rabeprazole, sertraline, and trimipramine.

CYP2C19 is a highly polymorphic enzyme that contributes to the metabolism of many clinically relevant drugs ([@MCS004531WILC66]; [@MCS004531WILC23]). Individuals can be categorized as ultra-rapid, rapid, intermediate, or poor metabolizers, depending on absent, decreased, normal, or increased function ([@MCS004531WILC58]). As shown in [Table 3](#MCS004531WILTB3){ref-type="table"}, we were able to determine that all three brothers had a no function copy of this gene (\*2B) and that both the eldest and youngest brothers have a \*1B second copy, whereas the middle brother\'s second allele is \*17. Thus, at best, the middle brother is an intermediate metabolizer, because the \*17 gain-of-function allele does not completely compensate for the no function allele.

Multiple genes encode CYP3A enzymes, with *CYP3A4* and *CYP3A5* regarded as the most important ([@MCS004531WILC63]). Expression is highly polymorphic with 52 *CYP3A4* and 26 *CYP3A5* star alleles cataloged ([@MCS004531WILC23]). All of the brothers were found to be homozygous for the two alleles that make up the *CYP3A5* \*3 haplotype (*CYP3A5* \*3/\*3) and are thus considered to be CYP3A5 non-expressors who may have decreased metabolism of a large percentage of oxidatively metabolized drugs ([@MCS004531WILC63]). This variation in expression is particularly important for drugs and substrates with narrow therapeutic indices, including the immunosuppressants cyclosporine and tacrolimus, and can result in clinically significant differences in toxicity and response ([@MCS004531WILC18]). Additional PGx related findings can be found in [Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004531/-/DC1).

DISCUSSION {#s3}
==========

[@MCS004531WILC48] stated that "\[t\]he not-too-distant future holds many more opportunities for discovery of CF gene modiﬁers ... whole-genome sequencing will expand GWAS-type studies to rare variant analyses." In support of their prediction, we suggest that our WGS assessment of the three brothers identified several variants that could predispose a patient to better or worse outcomes and that the combination of exploring for genetic modifiers plus pharmacogenomics variants could be valuable. It was particularly interesting to compare the mildly affected youngest brother with his siblings and observe notable differences in both potential genetic modifiers and pharmacogenomics factors.

We suggest that the variants identified in these brothers may contribute to their varying courses of CF lung disease, including a known disease-associated variant in *SERPINA 1* (middle and youngest), a known CF modifier ([@MCS004531WILC3]), and the *HFE* p.H63D variant found in a heterozygous state in the middle and eldest brother and in a homozygous state in the youngest brother. The former is known to increase risk of liver disease in CF ([@MCS004531WILC3]) and COPD and liver disease in otherwise healthy individuals ([@MCS004531WILC50]; [@MCS004531WILC27]). *HFE* variants have been reported to be present at a surprisingly high frequency among CF patients ([@MCS004531WILC14]; [@MCS004531WILC60]) and appear to be modifiers of lung disease severity based on accelerating pulmonary dysfunction ([@MCS004531WILC60]). This effect might be attributable to altering susceptibility to infections with many bacteria, including PA ([@MCS004531WILC39]).

The known deleterious *MBL2* p.R52C variant, which was heterozygous in the eldest and youngest brothers, has been associated with recurrent respiratory tract infections and greater bronchiectasis severity in patients with ciliary dyskinesia ([@MCS004531WILC51]). It has also been reported that mannose-binding lectin (MBL)-deficient CF patients are colonized with PA earlier compared to MBL-sufficient patients ([@MCS004531WILC28]; [@MCS004531WILC26]), and MBL has been linked to the age-related decline in lung function in CF patients ([@MCS004531WILC24]; [@MCS004531WILC51]). Consistent with these data, the eldest brother colonized PA at the youngest age.

Only the youngest brother was found to be heterozygous for a very rare nonsynonymous variant in the plasminogen gene (*PLG*; p.D238N). Plasminogen has been shown to directly bind to AF and individuals with PLG deficiency can have tracheobronchial fibrin deposits, which have been shown to impair the ciliary system, thereby predisposing to recurrent sinobronchial infections ([@MCS004531WILC57]). In a patient with CF in which mucociliary clearance is already compromised ([@MCS004531WILC9]), PLG deficiency may increase the risk of *Aspergillus* bronchitis or related symptoms ([@MCS004531WILC67]). The presence of the variant in the youngest brother is consistent with his deterioration after 12 yr of age, when he showed recurrent AF-positive cultures.

*CYP2C19* status explains ∼40% of the variability in response to azole antifungal agents for systemic use ([@MCS004531WILC4]). Given the potential severity of illness in CF patients with invasive fungal infections, it is critical that therapeutic antifungal concentrations be attained rapidly ([@MCS004531WILC4]; [@MCS004531WILC29]). Variability in response complicates optimal dosing and can increase (dependent on genotype) either risk of toxicity or risk of undertreatment ([@MCS004531WILC4]; [@MCS004531WILC29]). Of note, in this case, the youngest brother, who may be at increased risk for AF infection owing to modifiers, may also be at increased risk of toxicity at standard therapeutic antifungal dosage because of *CYP2C19* genotype. Although a lower dose may be necessary to avoid toxicity in such individuals, it is important to note that the severity of fungal infection--related disease combined with high variability in antifungal response already necessitates a therapeutic drug monitoring (TDM) approach that would be expected to dramatically reduce toxicity associated risk in this individual ([@MCS004531WILC5]).

Conclusions {#s3a}
-----------

Our data show that there is notable genomic variation in CF related loci across these three siblings with CF. A complex interplay between the risk to disease or infection conferred by genetic modifiers and the response to drugs used to treat the disease and infection as the result of pharmacogenomics were likely contributory to the clinical outcomes in these patients.

To our knowledge, this is the first application of WGS to individual patients with CF applied in an effort to clarify (and eventually predict) the course of the disease in a strategy of personalized/precision medicine. However, additional cohort studies are needed to further assess this hypothesis. We also suggest that analysis of WGS data initially generated for identification of causal or modifier variation might also provide useful for the generation of pharmacogenomics data. Clearly, further evaluation with regards to specificity, sensitivity, and reproducibility would be required.

METHODS {#s4}
=======

Summary of RCT Protocol {#s4a}
-----------------------

The Wisconsin RCT of NBS was initiated in April 1985, and patients were eligible for enrollment until July 1994. The protocol for this unique project was conducted before mandatory registration and has been described in detail elsewhere ([@MCS004531WILC20]). Relevant to this study, each patient was managed with an Evaluation and Treatment Protocol ([@MCS004531WILC19]) and had clinical outcome variables assessed systematically every 3 mo, along with regular nutritional status evaluations using anthropometry and biochemical markers. To evaluate lung disease, we used ([@MCS004531WILC21]) a combination of spirometry and longitudinal quantitative radiology annually and biannually, respectively, scoring the chest radiographs with the sensitive WCXR scoring method---a rating system that scores the severity of air trapping, peribronchial thickening, bronchiectasis, other indicators of infection, and atelectasis ([@MCS004531WILC40]). From this cohort of patients, we identified for WGS two brothers who as children showed lung disease course discordances---one, the youngest, was milder, whereas the middle brother appeared more severe than average---and a third, eldest brother (born before the RCT) also had severe lung disease.

Sample Handling and Whole-Genome Sequencing {#s4b}
-------------------------------------------

After we obtained IRB approvals from the University of Wisconsin Human Subjects Committee and written informed consent obtained directly for research and publication, we collected whole blood samples from each brother in 4 mL volumes, anticoagulated specimens with EDTA, and then harvested leukocytes from the postcentrifugation buffy coats. The middle brother\'s DNA was isolated from the blood sample at the University of Wisconsin, where the sample underwent WGS using an Illumina HiSeq 4000 instrument. The harvested leukocyte samples from the eldest and youngest brothers were sent frozen to HudsonAlpha Institute for Biotechnology for on-site DNA isolation using the QIAsymphony DSP DNA Mini Kit. The extracted DNA was then quantified using a Qubit system as well as using agarose gel electrophoresis to ensure sufficient yield and quality for sequencing. The eldest and youngest brothers' DNA samples were sequenced at HudsonAlpha Institute for Biotechnology\'s Genomic Services Laboratory using an Illumina HiSeqX paired-end 150-bp read methodology. Samples were sequenced to a mean depth of 35× coverage with \>80% of bases covered at 20×. Specific coverage information for variants reported is provided in [Table 2](#MCS004531WILTB2){ref-type="table"}.

Secondary and Tertiary Analyses {#s4c}
-------------------------------

Secondary and tertiary analyses followed standard methods ([@MCS004531WILC65]). In brief, sequences for each of the brothers were aligned to reference genome hg19 using BWA-mem according to standard protocols ([@MCS004531WILC41]). The aligned sequences were processed using the GATK package for base quality score recalibration, insertion/deletion realignments, duplicates removal, and discovery of single-nucleotide substitutions and small insertions and deletions, as well as genotyping ([@MCS004531WILC13]). Quality control metrics and sample swap tests were applied, including blinded CFTR genotype determinations and sample relationship metrics. The resultant variant files were loaded into the tertiary analysis software, Codicem (<http://envisiongenomics.com/codicem-analysis-platform/>), developed by the Worthey Laboratory at the HudsonAlpha Institute for Biotechnology. Coverage information for variants reported is provided in [Table 2](#MCS004531WILTB2){ref-type="table"}.

Codicem was used to analyze and support interpretation of the variant data (described elsewhere ([@MCS004531WILC32]). Preset filter steps were used to remove variants of poor quality as well as variants in genes on the American College of Medical Genetics list of 59 genetic conditions with no phenotype connection to CF ([@MCS004531WILC35]). This was used to reduce, if not eliminate, the potential for identifying incidental findings that should be returned, per the IRB-approved protocol. The filtering strategy used in Codicem also prioritized and excluded variants based on various in silico damage predictions, existing disease associations including CF modifiers (e.g., [@MCS004531WILC10]), phenotype terms, and population allele frequencies. This reduced the number of variants to be reviewed to those most likely to be significant. Variants passing these filters were reviewed by two variant analysts who further assessed variants based on their potential effect on gene function and CF pathogenesis/progression. Variants of interest were selected and passed to team review. Variants subsequently deemed likely contributory underwent Sanger confirmation. These analyses allowed us to create the list of potential genetic modifiers provided in [Supplemental Table 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a004531/-/DC1).

Pharmacogenomics Analysis {#s4d}
-------------------------

Pharmacogenomic definitions were downloaded from PharmGKB ([@MCS004531WILC2]), an expert-curated database, in order to build a pharmacogenomics database containing simple (i.e., single-variant) to complex (i.e., many-variant) haplotype/diplotype associations along with drug metabolism, response, and adverse reaction data. The association of pharmacogenomic findings for a given patient followed a three-step process. First, the pharmacogenomics annotation pipeline, an in-house application written in Java, gathered all relevant variant information for a patient from a variant call format (VCF) file. Next, diplotypes and genotypes were inferred using this data. Finally, pharmacologically relevant curations for each patient were extracted by matching haplotype to association data. All curations selected to be of interest were manually rereviewed by two analysts. Passing curations were categorized by drug class, as defined by Drug Bank ([@MCS004531WILC64]). Variants for drug classes of interest (e.g., antibiotics and immunosuppressants) were manually reviewed to identify potentially significant variant-drug combinations. Pharmacogenomic variants present in each of the brothers were automatically annotated with their respective effects matched to this database and subject to additional manual curation.
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Data Deposition and Access {#s5a}
--------------------------

Deidentified variant data has been submitted to ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) under accession numbers SCV001142519.1, SCV001142520.1, SCV001142521.1, SCV001142522.1, and SCV001142523.1. Raw sequencing data could not be deposited because of lack of consent.
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